About UsBlueskin provides unparalleled operational experience in medical dermatology, streamlining participant recruitment and reducing screen failures.
Blueskin was built on the foundation of the Sanos Group, and the combined experience of elements particularly important for clinical research in medical dermatology. The clinical trial operational expertise is based on the experience from NBCD, a CRO which has a track record of more than 20.000 randomized study participants across more than 200 sites, and the medical dermatology and Decentralized Clinical Trial (DCT) experience from Studies&Me, originally a spin-out of dermatology market leader Leo Pharma.
With the acquisition of Studies&Me mid-2022, Sanos Group now includes the experience and expertise of the previous medical dermatology innovation hub, which spent many years working with clinical trials and patient recruitment with special focus on dermatology and decentralized clinical trials. Combined with the expertise of the remaining sister companies of the Sanos Group, several studies within medical dermatology have been executed.
Studies&Me also brings the expertise of board-certified dermatologists, who have significant experience in remote assessing dermatological diseases, clinical trial methods and conduct. The work to evaluate the feasibility and performance of remote assessments of skin conditions by qualified dermatologists have been published in high-ranking international medical journals, and Studies&Me are considered pioneers in this area. The decentralized approach allows Blueskin to leverage the possibility to screen participants remotely to avoid redundant site visits and improve enrollment performance.